

Express Mail Label No.: EV 292547379 US

Date of Deposit: July 14, 2003

DOCKET NO: N00260.70058.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Shashoua et al.
Serial No: unassigned
Confirmation No: unassigned
Filed: Herewith
For: DHA-PHARMACEUTICAL AGENT CONJUGATES OF
TAXANES
Examiner: unassigned
Art Unit: unassigned

MAIL STOP Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. §1.114. No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;

3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
Shashoua et al., Applicant

By: 
Edward R. Gates, Reg. No. 31,616
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 720-3500

Docket No. N00260.70058.US
Date: July 14, 2003
XNDDX

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: unassigned		ATTY. DOCKET NO.: N00260.70058.US	
				FILING DATE: Herewith		CONFIRMATION NO.: unassigned	
				APPLICANT: Shashoua et al.			
				GROUP ART UNIT: unassigned		EXAMINER: unassigned	
Sheet	1	of	7				

U.S. Patent Documents

Exam Init	Ref Des	Document No.		Date	Name	FILING DATE If Appropriate
	*	2001/000692	A1	07-05-2001	Myhren et al.	
	*	6,291,690	B1	09-18-2001	Mayhew et al.	
	*	6,281,376		08-28-2001	Whittaker et al.	
	*	6,258,836			Shashoua	
	*	6,252,060		06-26-2001	Hostetler	
	*	6,225,460		05-01-2001	Bischofberger et al.	
	*	6,166,089		12-26-2000	Kozak	
	*	6,136,796		06-20-2000	Kozak	
	*	6,077,837		06-20-2000	Kozak	
	*	6,069,249		05-30-2000	Arimilli et al.	
	*	6,043,230		03-28-2000	Arimilli et al.	
	*	5,977,174	B1	11-02-1999	Bradley et al.	
	*	5,994,392		11-30-1999	Shashoua	
	*	5,985,854		10-24-2000	Kozak	
	*	5,977,089		11-02-1999	Arimilli et al.	
	*	5,977,061		11-02-1999	Holy et al.	
	*	5,922,695		07-13-1999	Arimilli et al.	
	*	5,716,614		02-10-1998	Katz et al.	
	*	5,459,256		10-17-1995	Marquez et al.	
	*	5,420,276		05-30-1995	Norbeck	
	*	5,223,263		06-29-1993	Hostetler et al.	
	*	5,194,654		03-16-1993	Hostetler et al.	
	*	5,059,699		10-22-1991	Kingston et al.	
	*	5,278,324		01-11-1994	Kingston et al.	
	*	5,534,499		07-09-1996	Ansell	
	*	6,291,690		09-18-2001	Mayhew et al.	
	*	5,925,669		07/1999	Katz, et al.	
	*	5,919,815		07/06/99	Bradley, et al.	
	*	5,814,456		09/29/98	O'Rand, et al.	
	*	5,795,909		08/18/98	Shashoua, et al.	
	*	5,750,572		05/12/98	Bruzzese	
	*	5,654,290		08/05/97	Bayon, et al.	
	*	5,604,216		02/18/97	Horrobin	
	*	5,597,719		01/28/97	Freed, et al.	
	*	5,580,899		12/03/96	Mayhew, et al.	
	*	5,580,556		12/03/96	Horrobin	
	*	5,516,800		05/14/96	Horrobin	
	*	5,504,102		04/02/96	Agharkar, et al.	

	*	5,484,876		2/94	Shashoua, et al.	
	*	5,484,809		01/16/96	Hostetler, et al.	
	*	5,496,714		03/05/96	Comb, et al.	
	*	5,494,999		02/27/96	Hale, et al.	
	*	5,476,954		12/19/95	Bourzat, et al.	
	*	5,473,055		12/05/95	Mongelli, et al.	
	*	5,468,754		11/21/95	Hausheer, et al.	
	*	5,453,521		09/26/95	Gaullier, et al.	
	*	5,453,520		09/26/95	Bombardelli, et al.	
	*	5,447,936		09/05/95	Hausheer, et al.	
	*	5,466,841		11/14/95	Horrobin, et al.	
	*	5,411,947		05/02/95	Hostetler, et al.	
	*	5,362,831		11/08/94	Mongelli, et al.	
	*	5,356,928		10/18/94	Murray et al.	
	*	5,352,596		10/04/94	Cheung, et al.	
	*	5,336,684		08/09/94	Murray, et al.	
	*	5,314,991		05/24/94	Oka, et al.	
	*	5,308,832		05/03/94	Garleb, et al.	
	*	5,276,020		1/94	Horribin, et al.	
	*	5,250,722		10/05/93	Bombardelli, et al.	
	*	5,246,726		09/21/93	Horrobin, et al.	
	*	5,223,263		06/29/93	Hostetler, et al.	
	*	5,216,142		06/01/93	Horribin, et al.	
	*	5,216,023		06/01/93	Literati-Nagy, et al.	
	*	5,214,062		05/25/93	Mark, et al.	
	*	5,194,654		03/16/93	Hostetler, et al.	
	*	5,169,764		12/92	Shooter, et al.	
	*	5,141,958		08/25/92	Crozier-Willi, et al.	
	*	5,120,760		06/09/92	Horrobin	
	*	5,116,624		05/26/92	Horrobin, et al.	
	*	5,112,863		05/12/92	Hashimoto, et al.	
	*	5,112,596		5/92	Malfroy-Camine	
	*	5,068,224		11/91	Fryklund, et al.	
	*	4,968,672		11/06/90	Jacobson, et al.	
	*	4,943,579		07/24/90	Vishnuvajjala, et al.	
	*	4,857,653		08/15/89	Colin, et al.	
	*	4,814,470		03/21/98	Colin, et al.	
	*	4,788,063		11/28/88	Fisher, et al.	
	*	4,729,989		03/08/88	Alexander	
	*	4,704,393		11/03/87	Wakabayashi, et al.	
	*	4,692,441		09/08/87	Alexander, et al.	
	*	4,636,494		01/13/87	Growden, et al.	
	*	4,407,744		10/83	D.M. Young	
	*	4,287,184		9/81	D.M. Young	
	*	4,185,095		1/80	D.M. Young	
	*	4,088,646		05/09/78	Ishida, et al.	
	*	6,080,877		06/27/00	Swindell, et al.	
	*	6,153,653	B1	11-28-2000	Shashoua	
	*	6,197,764	B1	03-06-2001	Bradley et al.	

	*	6,225,444	B1	05-01-2001	Shashoua	
--	---	-----------	----	------------	----------	--

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Office/Country	Publication Date	Name of Patentee or Applicant of Cited Document (not necessary)	Class	Sub Class	Translation	
							Yes	No
	*	0 350 287	10/90	EPO				
	*	0 693 498 A1	1/96	EPO				
	*	0 615 752 A1	9/94	EPO				
	*	0 030 009 A1	06/81	EPO				
	*	8163991A	06/25/96	Japan			X	
	*	DE 2602175	07/29/76	Germany				
	*	2 698 269 A	08/05/97	France				
	*	JP 9025231A	01/28/97	Japan			X	
	*	JP 8027010A	01/30/96	Japan			X	
	*	JP 76-9469	01/22/75	Japan				
	*	JP 6016548A	01/25/94	Japan			X	
	*	75-427/1983	4/83	Japan (English Abstract)			X	
	*	59025327A	02/09/84	Japan			X	
	*	JP 1153629A	06/15/89	Japan			X	
	*	1287022A	11/17/89	Japan			X	
	*	JP 1203331A	08/16/89	Japan			X	
	*	JP 9030963	2/97	Japan			X	
	*	JP 815133	6/96	Japan			X	
	*	JP 59-204175	11/84	Japan (English Abstract)				
	*	ZA 9603433A	10/30/96	South Africa				
	*	WO 98/32718	07/30/98	NORSK HYDRO				
	*	WO 98/21223	05/22/98	PCT				
	*	WO 97/44336	11/27/97	PCT (7018 WO)				
	*	WO 97/44063	11/27/97	PCT (7020 WO)				
	*	WO 97/44026	11/27/97	PCT (7019 WO)				
	*	WO 96/27380	09/96	PCT				
	*	WO 96/12696	05/96	PCT				
	*	WO 96/01259	1/1996	PCT				
	*	WO 95/33736	12/1995	PCT				
	*	WO 95/13271	5/1995	PCT				
	*	WO 95/13270	5/1995	PCT				
	*	WO 95/01969	1/1995	PCT				
	*	WO 94/24107	10/1994	PCT				
	*	WO 94/13654	6/1994	PCT				
	*	WO 94/12530	6/1994	PCT				
	*	WO 94/11547	5/1994	PCT				
	*	WO 94/07880	4/1994	PCT				
	*	DE 422 4737	2/94	Germany				
	*	WO 94/22887	10/1994	PCT				

	*	WO 94/12530	6/1994	PCT				
	*	WO 93/00919	01/21/93	PCT				
	*	WO 92/20362	11/26/92	PCT (7007 WO)				
	*	WO 92/16554	10/92	PCT				
	*	WO 99/52887	10/21/99	PCT				
	*	WO 93/11668	06/24/93	PCT				
	*	WO 90/00555	01/25/90	PCT				
	*	WO 89/02733	04/06/89	PCT				

Other Art

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.		
	*	CHEN, et al. "Taxol Structure-Activity Relationships: Synthesis and Biological Evaluation of Taxol Analogs Modified at C-7," <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 4, No. 18, pp. 2223-2228, 1994.		
	*	DE GROOT, et al., "Synthesis and Biological Evaluation of 2'-Carbamate-Linked and 2'-Carbonate-Linked Prodrugs of Paclitaxel: Selective Activation by the Tumor-Associated Protease Plasmin," <i>J. Med. Chem.</i> , 2000, Vol. 43, pp. 3093-3102.		
	*	DISCHINO, et al., "Synthesis of Monosodium Salt of Carbon-14 Labeled Paclitaxel (Taxol®) 2'-Ethyl Carbonate 7-Phosphonooxymethyl Ether, a Potential Prodrug of Paclitaxel," <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , Vol. XXXIX, No. 2.		
	*	GREENWALD, et al., "Highly Water Soluble Taxol Derivatives: 7-Polyethylene Glycol Carbamates and Carbonates," <i>J. Org. Chem.</i> , 1995, Vol. 60, pp. 331-336.		
	*	HALMOS, et al. "Fatty Acid Conjugates of 2'-Deoxy-5'-Fluorouridine as Prodrugs for the Selective Delivery of 5-Fluorouracil to Tumor Cells" <i>Biochemical Pharmacology</i> , (1992) 44:1:149-155.		
	*	HONG et al., "Nucleoside-ether lipid conjugates as biotransformed prodrugs of antitumor and antiviral nucleosides" <i>Journal of Lipid Mediators and Cell Signalling</i> . 10: 159-161 (1994).		
	*	KARMALI, R., "N-3 Fatty Acids: Biochemical Actions In Cancer", <i>J. Nutr. Sci. Vitaminol. (Tokyo)</i> , (1992), 148-152. (Abstract)		
	*	MINAMI, M., et al., "Effects Of Low-Dose Eicosapentaenoic Acid, Docosahexaenoic Acid And Dietary Fat On The Incidence, Growth And Cell Kinetics Of Mammary Carcinomas In Rats", <i>Oncology</i> , (1996), 53(5):398-405.		
	*	UEDA et al., "Synthesis and Antitumor Evaluation of 2'-Oxycarbonylpaclitaxels (Paclitaxel02'-Carbonates)", <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 4, No. 15, pp. 1861-1864, 1994.		
	*	ANSARI et al., "Fatty acid conjugates of xenobiotics," <i>Toxicol. Lett.</i> (1995), 75, 1-17.		
	*	Anel, A., et al., "Increased Cytotoxicity Of Polyunsaturated Fatty Acids On Human Tumoral B And T-Cell Lines Compared With Normal Lymphocytes", <i>Leukemia</i> , (1992), 6(7):680-688.		
	*	Anel, B., et al. "Cytotoxicity Of Chlorambucil And Chlorambucil-Fatty Acid Conjugates Against Human Lymphomas And Normal Human Peripheral Blood Lymphocytes", <i>Biochem Pharmacol.</i> , (1990), 40(6):1193-1200.		
	*	Begin, M.E., et al., "Differential Killing Of Human Carcinoma Cells Supplemented With N-3 And N-6 Polyunsaturated Fatty Acids", <i>J Natl Cancer Inst</i> , (1986), 77(5):1053-1062. (Abstract)		
	*	Bourat, et al., "Long Chain Esters of Pipotiazine as Long-Acting Psychotropic Pro-Drug", <i>Med. Chem. Proc. Int. Symp.</i> 5th (1976) pp. 105-114.		
	*	Braam, J., et al., <i>Cell</i> , 60"357-364 (1990)		
	*	Burns, C.P., et al., "Effect Of Docosahexaenoic Acid On Rate Of Differentiation Of HI-60 Human Leukemia", <i>Cancer Res</i> , (1989), 49:3252-3258.		
	*	Carboni et al., "Synthesis of a Photoaffinity Analog of Taxol as an Approach to Identify the Taxol Binding Site on Microtubules", <i>Journal of Medicinal Chem.</i> (8 September 1992).		
	*	Chajes, V., et al., "Influence Of N-3 Fatty Acids On The Growth Of Human Breast Cancer Cells In Vitro: Relationship To Peroxides And Vitamin-E", <i>Breast Cancer Res Treat</i> , (1995), 34:199-212.		
	*	de Antueno, R.J., et al., "In Vitro Effect Of Eicosapentaenoic And Docosahexaenoic Acids On Prostaglandin E2 Synthesis In A Human Lung Carcinoma", <i>Biochem Int</i> , (1989), 19(3):489-496. (Abstract)		
	*	de Smidt, P.C., et al., "Characteristics Of Association Of Oleoyl Derivatives Of 5-Fluorodeoxy-Uridine And Methotrexate With Low-Density Lipoproteins (Ldl)", <i>Pharm Res</i> , (1992), 9(4):565-569.		

	*	Deutsch, H.F., et al., "Cytotoxic Effects Of Daunomycin-Fatty Acid Complexes On Rat Hepatoma", <i>CELLS</i> , <i>Cancer Res</i> , (1983), 43:2668-2672.
	*	D'Orlando, et al., "Citicoline (CDP-Choline): Mechanisms of Action and Effects in Ischemic Brain Injury", <i>Neurol. Res.</i> (1995) 17: 281-284
	*	Ehringer, W., et al., "A Comparison Of The Effects Of Linolenic (18:3 Omega 3) And Docosahexaenoic (22:6 Omega 3) Acids On Phospholipid Bilayers", <i>Chem Phys Lipids</i> , (1990), 54:79-88.
	*	Ertel, et al., "Type III -Agatoxins: A Family of Probes for Similar Binding Sites on L- and N-Type Calcium Channels", <i>Biochemistry</i> , 33:5098-5108 (1994)
	*	Falconer, J.S., et al., "Effect Of Eicosapentaenoic Acid And Other Fatty Acids On The Growth <i>In Vitro</i> Of Human Pancreatic Cancer Cell Lines", <i>Br. J. Cancer</i> , (1994,) 69:826-832.
	*	Ferrari et al., "9-Cis-6,6'-Diapo-Gamma, Gamma-Carotenedioic Acid Derivatives And Pharmaceutical Compositions Containing Them", p. 710. Abs. 20423w, <i>Chem. Abs.</i> 95(23), 12/7/81, EP30,009 06/10/81 06/10/81
	*	Georg et al., "The Medicinal Chemistry of Taxol", in "Taxol Science and Applications" ed. Matthew Suffness. Boca Raton: CRC Press, Inc., 1995, pp. 317-375.
	*	Hesse et al., "Inhibitory Effect of Cholesteryl- -Aminobutyrate" <i>Neurolpharmacology</i> , Vol. 24, No. 2, pp. 139-146 (1985)
	*	Higuchi et al., (Editors), Prodrugs as Novel Drug Delivery Systems, <i>Acs Symposium Series</i> , vol. 14, ACS, Washington, 1975, pp. 14-15.
	*	Iwakami, et al., "Inhibition of Arochidonate 5-Lipoxygenase by Phenolic Compounds", <i>Chem. Pharm. Bull. (Japan)</i> , 34(9), 3960-3963 (1986)
	*	Jacob, et al., -Aminobutyric Acid Esters.1. Synthesis...", <i>Journal of Medicinal Chemistry</i> , Vol. 28, No. 1, pp 106-110 (1985)
	*	Jacobson, K., et al., Adenosine analogs with covalently attached lipids have enhanced potency at A1-adenosine receptors, <i>FEBS Letters</i> 225:1,2:97-102, (1987).
	*	Jenski, L.J., et al., "Docosahexaenoic Acid-Induced Alteration Of Thy-1 And Cd8 Expression On Murine Splenocytes", <i>Biochim Biophys Acta</i> , (1995), 1236(1):39-50.
	*	Jenski, L.J., et al., "Omega 3 Fatty Acids Increase Spontaneous Release Of Cytosolic Components From Tumor Cells", <i>Lipids</i> , (1991), 26(5):353-358.
	*	Jenski, L.J., et al., "Omega-3 Fatty Acid-Containing Liposomes In Cancer Therapy", <i>Proc Soc Exp Biol Med</i> , (1995), 210(3):227-233.
	*	Karmali, R.A., et al., "Effect Of Omega-3 Fatty Acids On Growth Of A Rat Mammary Tumor", <i>J Natl Cancer Inst</i> (1984), 73(2):457-461. (Abstract)
	*	Karmali, R., "N-3 Fatty Acids: Biochemical Actions In Cancer", <i>J. Nutr. Sci. Vitaminol. (Tokyo)</i> , (1992), 148-152. (Abstract)
	*	Kinsella, J.E., et al., "Effects Of Polyunsaturated Fatty Acids On The Efficacy Of Antineoplastic Agents Toward L5178y Lymphoma Cells", <i>Biochem Pharmacol</i> , (1993), 45(9):1881-1887. (Abstract)
	*	Kretsinger, R. H., et al., "The EF-Hand, Homologs and Analogs", <i>Novel Calcium-Binding Proteins</i> , 17-37 (1991)
	*	Madhavi, N., et al., "Effect Of N-6 And N-3 Fatty Acids On The Survival Of Vincristine Sensitive And Resistant Human Cervical Carcinoma Cells <i>In Vitro</i> ", <i>Cancer Lett</i> , (1994), 84:31-41.
	*	Makino, et al., <i>Chemical Abstracts</i> , Vol. 106, No. 12, (90177x) issued 23 March 1987, "Pharmaceuticals Permeable to Blood-Brain Barrier".
	*	Marsden, B. J., et al., "H NMR Studies of Synthetic Peptide Analogues of Calcium-Bining Site III of Rabbit Skeletal Troponin C: Effect of the Lanthanum Affinity of the Interchange of Aspartic Acid and Asparagine Residues at the Metal Ion Coordinating Positions", <i>Biochemistry</i> , 27:4198-4206 (1988)

	*	Mazumdar, et al., "Preparation and Evaluation of Ethambutol Derivatives", <i>Indian J. Pharm. Sci.</i> 47(6): 179-180 (1985)
	*	Minami, M., et al., "Effects Of Low-Dose Eicosapentaenoic Acid, Docosahexaenoic Acid And Dietary Fat On The Incidence, Growth And Cell Kinetics Of Mammary Carcinomas In Rats", <i>Oncology</i> , (1996), 53(5):398-405.
	*	Nicolaou et al., "Design, Synthesis and Biological Activity of Protaxols", <i>Nature</i> , 364: 464-466 (July).
	*	Nishio, et al., "Novel Water-soluble Derivatives of Docosahexaenoic Acid Increase Diacyl-Glycerol Production Mediated by Phosphatidylcholine-Specific Phospholipase C", <i>Proc. Soc. Exp. Biol. Med.</i> (1993) 203(2):200-208.
	*	Oshima, M., et al., "Effects Of Docosahexaenoic Acid (Dha) On Intestinal Polyp Development In Apc Delta 716 Apc Delta 716 Knockout Mice", <i>Carcinogenesis</i> , (1995), 16(11):2605-2607.
	*	Pascale, A.W., et al., "Omega-3 fatty acid modification of membrane structure and function. Alteration by docosahexaenoic acid of tumor cell sensitivity to immune cytotoxicity", <i>Nutr Cancer</i> , (1993), 19(2):147-157.
	*	Plumb, J.A., et al., "Effect Of Polyunsaturated Fatty Acids On The Drug Sensitivity Of Human Tumour Cell Lines Resistant To Either Cisplatin Or Doxorubicin", <i>Br J Cancer</i> , (1993), 67:728-733.
	*	POUILLART, "Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies," <i>Life Sci.</i> (1998), 63(20), 1739-1760.
	*	Rocco et al., "Models of Fibronectin", <i>The EMBO Journal</i> , 6: 2343-2349 (1987).
	*	Rose, W.C., Preclinical Antitumor Activity of Taxanes", in "Taxol Science and Applications" ed. Matthew Suffness. Boca Raton: CRC Press, Inc., 1995, pp. 317-375.
	*	Schabitz, et al., "The effects of Prolonged Treatment with Citicoline in Temporary Experimental Focal Ischemia", <i>J. Neurol. Sci.</i> , (1996) 138(1-2):21-25 (Abstract)
	*	Shashoua, et al., "-Aminobutyric Acid Esters.1. Synthesis...", <i>J. of Med. Chem.</i> , Vol. 27, pp. 659-664 (1984)
	*	Shea, et al., <i>Developmental Brain Research</i> , 21:307-314 (1985).
	*	Specter, R., "Fatty Acid Transport Through the Blood-Brain Barrier.", <i>J. of Neurochem.</i> , 50:2:639-643 (1988)
	*	Suphioglu, C., et al., "Molecular Cloning and Immunological Characterization of Cyn d 7, A Novel Calcium-Binding Allergen from Bermuda Grass Pollen", <i>FEBS Letters</i> , 402:167-172 (1997)
	*	Swindell, et al., "Characterization of the Taxol Structure-Activity Profile for the Locus of the A-Ring Side Chain Side Chain", <i>Bioorganic & Medicinal Chem. Ltrs.</i> , Vol.4, No. 12, pp. 1531-1536. (1994)
	*	Tessier, C., et al., "Docosahexaenoic Acid Is A Potent Inhibitor Of Rat Uterine Stromal Cell Proliferation", <i>Biochem Biophys Res Commun</i> , (1995), 207(3):1015-1021.
	*	Tinsley, I.J., et al., "Influence Of Dietary Fatty Acids On The Incidence Of Mammary Tumors In The C3h Mouse", <i>Ch3h Mouse</i> ", <i>Cancer Res</i> , (1981), 41:1460-1465.
	*	Young, et al., <i>FEBS Letters</i> , 338:212-216 (1994)
	*	Zerouga, M., et al., "Phospholipid Class As A Determinant In Docosahexaenoic Acid's Effect On Tumor Cell Viability", <i>Anticancer Res</i> , (1996), 16:2863-2868. (Abstract)
	*	Zijlstra, J.G., et al., "Influence Of Docosahexaenoic Acid In Vitro On Intracellular Adriamycin Concentration In Lymphocytes And Human Adriamycin-Sensitive And Resistant Small-Cell Lung Cancer Cell Lines, And On Cytotoxicity In The Tumor Cell Lines", <i>Int J Cancer</i> , (1987), 40:850-856.
	*	International Search Report, PCT/US 00/06160, International Filing Date: 09/03/2000

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/846,838, filed May 1, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]